期刊文献+

下调脐静脉内皮细胞小窝蛋白1表达对RPMI8226细胞硼替佐米敏感性的影响

Sensitivity to bortezomib of RPIM8226 cells after co-cultured with down-regulated Cav-1 expression
原文传递
导出
摘要 目的探讨下调脐静脉内皮细胞(HUVEC)小窝蛋白1(Cav.1)表达对多发性骨髓瘤细胞硼替佐米敏感性的影响。方法构建靶向Cav-1基因的shRNA表达载体及阴性对照shRNA表达载体,转染HUVEC细胞株;以多发性骨髓瘤细胞系RPMl8226为对象,用MTT法检测不同浓度硼替佐米单独或联合50nmol/L地塞米松对单独培养及与HUVEC(转染干扰质粒或对照质粒)间接共培养的RPMl8226细胞增殖的抑制作用;用Western blot法检测Cav.1表达水平;用流式细胞术检测细胞周期、细胞凋亡率及活性氧(P.OS)水平变化。结果Cav.1shRNA.1转染的HuVEc(HuVEc。low)Cav-1蛋白表达水平与转染阴性对照载体组相比显著降低,其Cav-1蛋白相对表达水平为0.2199±0.0288对1.3195±0.2393(P〈0.01);RPMl8226细胞单独培养及与HUVEC、HUVEC共培养,硼替佐米作用的IC50值分别为20、50、65nmol/L。HUVEC、HUVEC可使RPMl8226细胞周期阻滞,RPMl8226细胞单独培养及与HUVEC、HUVEC共培养后RPMl8226细胞G0/G1期比例分别为28.5%、30.4%和36.2%;HUVEC保护RPMl8226细胞免于凋亡,20nmol/L硼替佐米作用于单独培养及与HUVEC、HUVEC共培养的RPMl8226细胞24h后,其细胞凋亡和(或)死亡率分别为66.8%、10.7%和8.6%;RPMl8226细胞可诱导HUVEC的氧化应激,共培养前后RPMl8226细胞ROS水平由15.0%上升至35.2%,HUVEC的ROS水平由80.4%上升至91.0%,HUVEC ROS水平由84.6%上升至96.8%。结论下调HUVECCav一1表达可促进共培养的RPMl8226细胞增殖,抑制细胞凋亡,使其阻滞在静息期,并降低RPMl8226对硼替佐米的敏感性。 Objective To investigate the sensitivity to bortezomib of RPMI8226 cells after co-cultured with down-regulated Caveolin (Cav) -1 expression of HUVECs by transfeetion with Cav-1 shRNA (HUVEC ). Methods Exposure to bortezomib with or without 50 nmol/L dexamethasone at different concentration, the proliferation of RPMI8226 was analyzed by MTT assay when it was cultured alone or co-cultured with HUVEC. Cav-1 expression was detected by using of Western blot and cell cycle, apoptosis and the level of reactive oxygen species (ROS) were analyzed by flow cytometry. Results Cav-1 expression was notably down-regulated in HUVECscav (0.2199±0.0288 vs 1.3195±0.2393 ) (P〈0.01). The IC50 of bortezomib for RPMI8226 cultured alone, co-cultured with HUVECs or HUVECC were 20 nmol/L, 50 nmol/L and 65 nmol/L, respectively. The percentages of G0-G1 phase in RPMI8226 cultured alone, co-cultured with HUVECs and HUVECscavow were 28.49%, 30.41%, and 36.15% respectively. The protection of RPMI 8226 against apoptosis by HUVECs was demonstrated that the apoptosis/death rates were 66.8%, 10.7% and 8.6% in RPMI8226 cultured alone, co-cultured with HUVECs and HUVECsc after exposure to 20 nmol/L bortezomib for 24 h. RPMI8226 could induce the oxidative stress of HUVECs before and after co-culture. The ROS level was raised from 15.0% to 35.2% in RPMI8226, from 80.4% to 91.0% in HUVECs, and from 84.6% to 96.8% in HUVECs. Conclusion The down-regulated Cav- I expression of HUVECs could promote proliferation and induce apoptosis of RMPI8226 cells, lead to G,JG, phase arrest, and reduce the sensitivity to bortezomib.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2013年第11期946-951,共6页 Chinese Journal of Hematology
基金 国家自然科学基金(81071934、81272631)
关键词 人脐静脉内皮细胞 基因 Car-1 多发性骨髓瘤 硼替佐米 Human umbilical veins endothelial cells Gene, Cav-1 Multiple myeloma: Bortezomib
  • 相关文献

参考文献12

  • 1Stahlhut M, Sandvig K, van Deurs B, et al. Caveolae: uniform structures with multiple functions in signaling, cell growth, and cancer. Exp Cell Res, 2000, 261:111-118.
  • 2Lin MI, Yu J, Murata T, et al. Caveolin- 1-deficient mice have in- creased tumor microvascular permeability, angiogenesis, and growth. Cancer Res, 2007,67:2849-2856.
  • 3Witkiewicz AK, Dasgupta A, Sotgia F, et al. An Absence of stro- mal caveolin- 1 expression predictsearly tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol, 2009,174:2023-2034.
  • 4Podar K, Tai YT, Cole CE, et al. Essential role of caveolae in Interleukin-6- and Insulin-like growth factor I-triggered Akt- 1- mediated survival of multiple myeloma cells. J Biol Chem, 2003,21:5794-5801.
  • 5Podar K, Shringarpure R, Tai YT, et al. Caveolin- 1 is required for vascular endothelial growth factor-triggered multiple myelo- ma cell migration and is targeted by bortezomib. Cancer Res, 2004,64:7500-7506.
  • 6Mercier I, Jasmin JF, Pavlides S, et al. Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders. Lab Invest, 2009, 89: 614-623.
  • 7Cohen AW, Hnasko R, Schubert W, et al. Role of caveolae and caveolins in health and disease. Physiol Rev, 2004, 84: 1341-1379.
  • 8Buda G, Ricci D, Huang CC,et al.Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol, 2010, 89:1133-1140.
  • 9Nojima M, Maruyama R, Yasui H, et al. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res, 2009, 15:4356-4364.
  • 10Bissell MJ, Radisky DC, Rizki A, et al. The organizing principle microenvironmental influences in the normal and malignant breast. Differentiation, 2002, 70:537-546.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部